ATEM Capital

ATEM Capital is a New York-based venture capital firm specializing in investments within the life sciences sector. The firm focuses on breakthrough technologies in BioPharma, MedTech, and Digital Health, with prioritized therapeutic areas including oncology, autoimmune diseases, rare diseases, and neurology. ATEM Capital has a history of successful co-investments with leading venture firms in the U.S. and Europe, as well as corporate venture firms such as Pfizer, Roche, J&JDC, and Novo. The team members have extensive experience in product launches, investment management, and exits of venture-backed companies, having invested over $30 billion overall.

The firm's investment strategy encompasses various stages, including early-stage venture, late-stage venture, private equity, and venture investments. ATEM Capital's geographical focus spans the United States and Europe, reflecting its commitment to fostering innovation in the life sciences industry across these regions. The firm's diverse portfolio includes companies in biotechnology, healthcare, medtech, and digital health sectors, underscoring its broad interest in transformative healthcare solutions.

ATEM Capital's leadership comprises professionals with diverse backgrounds in investments, scientific research, clinical development, intellectual property, and operations. This multidisciplinary team approach enables the firm to identify and support innovative companies that have the potential to make significant impacts in the healthcare and life sciences sectors.